NCT00334048View on ClinicalTrials.gov

Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo

PHASE4CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

Sexual Dysfunction

Interventions

DRUG

Ropinirole (Requip)

1 mg extended release formulation given once per day to a maximum of 4 per day

Trial Locations (1)

10019

Mood Disorders Research Program, New York

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

St. Luke's-Roosevelt Hospital Center

OTHER